Accelerated Medical Diagnostics,

Inc.

George D. Cimino, Paul T. Henderson, William Hope, Maike Zimmermann

PlatinDx

Diagnostic test to predict sensitivity towards

platinum based chemotherapeutics

Customers Interviews: 100

William George Paul Maike

MBA PhD PhD, CEO PhD

Market Opportunity Assessment

Resegmented Market

Total Available Market (TAM): $5B

Solid Cancers treated with Chemo Worldwide

Served Available Market (SAM): $1B

Cancers in the US

Target Market (TM): $250M

Bladder Cancer US TAM

SAM

TM

PlatinDx work flow

AMD activity before UCSF LLP

2010 2012

Business

Plan v1

IND/IRB

Approvals

(lung, bladder)

1st Patient

Microdosed

SBIR

P1

IND/IRB

Approvals

(breast)

SBIR

P2UCSF

LLPAMD

Formed

Idea To

IPO

Business

Plan v2

2008 2014

LLP program led to a focus on

bladder cancer

Initial Hypothesis Canvas

Out of the Building Learning & Focus

Hypothesis Reality

Oncologists and patients make

the treatment decision

Surgeons make the treatment

decision

Physician follow Standard of

Care set by ASCO and NCCN

Only 10% of patients are treated

with chemotherapy before

surgery

All initial value propositions are

equally important (saving

money, reducing toxic exposure,

improving reputation)

Minimizing unnecessary toxicity

and saving lives through

improving utilization of standard

of care are most important

FDA approval is important for

physician adoption

No, but may still be important for

reimbursement

Improved understanding

New possible value proposition:

Improve utilization of standard of

care recommendation

Model to visualize the improvement of live

expectancy with our test

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

0 12 24 36 48 60 72 84 96 108 120 132 144 156 168

% S

urv

ival

Months after Randomization

Chemo responders

Overall survival(responders/non-responders)

No chemoCurrent practice10% patients with Chemo

60 months median

survival extension

Next Steps

Tool provides a dynamic display of changing

diagnostic assay parameters on survival curves

Use the model to obtain desired performance

parameters from physicians for their adoption of

PlatinDx

Creating a pharmacoeconomic model of the effect

of PlatinDx usage to validate value added pricing

Final Canvas

Financial and Operational Milestones

2013 2014 2015 2016 2017 2018 2019 2020 2021

Investment Readiness Level Level Dx 7- 8

Reimbursement and IP strategies

understood but not fully implemented

Left side of canvas hypotheses tested

with some interviews

Revenue model validated

Market size validated

Right side of the canvas completed

and validated

Fund raising and clinical trials in

progress

LLP focused us on bladder cancer MVP as initial product

Acknowledgements

LLP

UCSF

NIH

Team

Mentors

Instructors

TAs

Interviewees

my car

Invention of coffee

German-English dictionary

…

Additional Information/Backup Slides

Out of the Building Learning & Focus

Surgeons decide how patients are treated

Bladder cancer is under treated with chemotherapy

because of low response rates (40%)

A 50-60% response rate is sufficient to change surgeon

adherence to SOC

Surgeons and oncologists rely more on peer reviewed

clinical studies compared to FDA approval for adoption

of new procedures

Microdose of

[14C]chemo drug( )*

*

*

**

* *

PlatinDx how it works

DNA

Accelerator Mass

Spectrometry (AMS)

* *****

**SensitiveResistant

orResults

Treatment decision

Blood/ Tumor

Samples

*

Blood Test or Tumor Test

Customer relationship “get, keep, grow”

What is your customer lifetime value?

• Urologist: $200,000 (US)

• 8000 specialists in the US

• 72,500 new bladder cancer cases per year

• assumed 5 year product lifetime

Customer Acquisition Cost $12,500

• Marketing and Sales budget / Customer

Segment Physician

PlatinDx

price

structure

Ecosystem